Quezada; Sergio
Patent Applications and Registrations
Patent applications and USPTO patent grants for Quezada; Sergio.The latest application filed is for "modulation of t cell cytotoxicity and related therapy".
- Quezada; Sergio - US
- Quezada; Sergio - London GB
- Quezada; Sergio - New York NY
| Patent | Date |
|---|---|
| Modulation Of T Cell Cytotoxicity And Related Therapy App 20220241333 - Quezada; Sergio ; et al. | 2022-08-04 |
| "Immune checkpoint intervention" in cancer Grant 11,098,121 - McGranahan , et al. August 24, 2 | 2021-08-24 |
| Anti-cd25 Antibody Agents App 20210054084 - Goubier; Anne ; et al. | 2021-02-25 |
| Anti-cd25 For Tumour Specific Cell Depletion App 20210047420 - Goubier; Anne ; et al. | 2021-02-18 |
| Anti-cd25 For Tumour Specific Cell Depletion App 20210040221 - Goubier; Anne ; et al. | 2021-02-11 |
| Anti-cd25 Antibody Agents App 20210009699 - Goubier; Anne ; et al. | 2021-01-14 |
| Anti-cd25 For Tumour Specific Cell Depletion App 20210009703 - Goubier; Anne ; et al. | 2021-01-14 |
| Anti-cd25 For Tumour Specific Cell Depletion App 20210009702 - Goubier; Anne ; et al. | 2021-01-14 |
| Anti-cd25 For Tumour Specific Cell Depletion App 20210009704 - Goubier; Anne ; et al. | 2021-01-14 |
| Anti-cd25 Antibody Agents App 20200407454 - Goubier; Anne ; et al. | 2020-12-31 |
| Anti-CD25 antibody agents Grant 10,752,691 - Goubier , et al. A | 2020-08-25 |
| Anti-CD25 antibody agents Grant 10,745,485 - Goubier , et al. A | 2020-08-18 |
| Anti-CD25 antibody agents Grant 10,738,125 - Goubier , et al. A | 2020-08-11 |
| Fc-optimized Anti-cd25 For Tumor Specific Cell Depletion App 20200010554 - Goubier; Anne ; et al. | 2020-01-09 |
| Method for Treating Cancer App 20200000903 - McGranahan; Nicholas ; et al. | 2020-01-02 |
| Neo-antigen Specific T Cells App 20200000904 - McGranahan; Nicholas ; et al. | 2020-01-02 |
| Anti-cd25 Antibody Agents App 20190322752 - Goubier; Anne ; et al. | 2019-10-24 |
| Anti-cd25 Antibody Agents App 20190300613 - GOUBIER; ANNE ; et al. | 2019-10-03 |
| Anti-cd25 Antibody Agents App 20190284287 - Goubier; Anne ; et al. | 2019-09-19 |
| Regulatory T Cell Mediator Proteins And Uses Thereof App 20190170729 - NOELLE; Randolph J. ; et al. | 2019-06-06 |
| Anti Cd25 Fc Gamma Receptor Bispecific Antibodies For Tumor Specific Cell Depletion App 20190135925 - Quezada; Sergio ; et al. | 2019-05-09 |
| "immune Checkpoint Intervention" In Cancer App 20180251553 - McGranahan; Nicholas ; et al. | 2018-09-06 |
| Method For Treating Cancer App 20180064793 - Mcgranahan; Nicholas ; et al. | 2018-03-08 |
| Regulatory T Cell Mediator Proteins And Uses Thereof App 20140004537 - Noelle; Randolph J. ; et al. | 2014-01-02 |
| Regulatory T cell mediator proteins and uses thereof Grant 8,465,740 - Noelle , et al. June 18, 2 | 2013-06-18 |
| Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity Grant 8,236,304 - Noelle , et al. August 7, 2 | 2012-08-07 |
| Regulatory T Cell Mediator Proteins And Uses Thereof App 20120195894 - Noelle; Randolph J. ; et al. | 2012-08-02 |
| Regulatory T Cell Mediator Proteins and Uses Thereof App 20080287358 - Noelle; Randolph J. ; et al. | 2008-11-20 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 